craft-sa-dev Home  

PMC:1283364 / 61012-62158 JSONTXT 5 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T12874 0-2 IN denotes In
T12876 3-10 NN denotes summary
T12877 10-12 , denotes ,
T12878 12-14 PRP denotes we
T12875 15-26 VBP denotes demonstrate
T12879 27-31 IN denotes that
T12881 32-42 VBG denotes abrogating
T12882 43-45 NN denotes Aβ
T12883 46-56 NN denotes production
T12880 57-62 VBZ denotes halts
T12884 63-66 DT denotes the
T12885 67-78 NN denotes progression
T12886 79-81 IN denotes of
T12887 82-92 JJ denotes pathologic
T12888 93-100 NNS denotes changes
T12889 101-103 IN denotes in
T12890 104-105 DT denotes a
T12892 106-116 JJ denotes transgenic
T12893 117-122 NN denotes mouse
T12891 123-128 NN denotes model
T12894 129-131 IN denotes of
T12895 132-141 NNP denotes Alzheimer
T12897 141-142 HYPH denotes -
T12896 142-146 NN denotes type
T12898 147-158 NN denotes amyloidosis
T12899 158-159 . denotes .
T12900 159-294 sentence denotes However, despite dramatic reductions in Aβ synthesis, neuritic plaques are stable structures in vivo that do not quickly disaggregate.
T12901 160-167 RB denotes However
T12903 167-169 , denotes ,
T12904 169-176 IN denotes despite
T12905 177-185 JJ denotes dramatic
T12906 186-196 NNS denotes reductions
T12907 197-199 IN denotes in
T12908 200-202 NN denotes Aβ
T12909 203-212 NN denotes synthesis
T12910 212-214 , denotes ,
T12911 214-222 JJ denotes neuritic
T12912 223-230 NNS denotes plaques
T12902 231-234 VBP denotes are
T12913 235-241 JJ denotes stable
T12914 242-252 NNS denotes structures
T12915 253-255 FW denotes in
T12916 256-260 FW denotes vivo
T12917 261-265 WDT denotes that
T12919 266-268 VBP denotes do
T12920 269-272 RB denotes not
T12921 273-280 RB denotes quickly
T12918 281-293 VB denotes disaggregate
T12922 293-294 . denotes .
T12923 294-490 sentence denotes It is possible that a combination of therapies to limit Aβ production, increase Aβ degradation, and enhance phagocytosis of deposited amyloid may be required to reverse damage associated with AD.
T12924 295-297 PRP denotes It
T12925 298-300 VBZ denotes is
T12926 301-309 JJ denotes possible
T12927 310-314 IN denotes that
T12929 315-316 DT denotes a
T12930 317-328 NN denotes combination
T12931 329-331 IN denotes of
T12932 332-341 NNS denotes therapies
T12933 342-344 TO denotes to
T12934 345-350 VB denotes limit
T12935 351-353 NN denotes Aβ
T12936 354-364 NN denotes production
T12937 364-366 , denotes ,
T12938 366-374 VB denotes increase
T12939 375-377 NN denotes Aβ
T12940 378-389 NN denotes degradation
T12941 389-391 , denotes ,
T12942 391-394 CC denotes and
T12943 395-402 VBP denotes enhance
T12944 403-415 NN denotes phagocytosis
T12945 416-418 IN denotes of
T12946 419-428 VBN denotes deposited
T12947 429-436 NN denotes amyloid
T12948 437-440 MD denotes may
T12949 441-443 VB denotes be
T12928 444-452 VBN denotes required
T12950 453-455 TO denotes to
T12951 456-463 VB denotes reverse
T12952 464-470 NN denotes damage
T12953 471-481 VBN denotes associated
T12954 482-486 IN denotes with
T12955 487-489 NN denotes AD
T12956 489-490 . denotes .
T12957 490-672 sentence denotes However, if started early enough in the course of disease, secretase inhibitors alone could provide substantial benefit in slowing pathogenic processes linked to amyloid deposition.
T12958 491-498 RB denotes However
T12960 498-500 , denotes ,
T12961 500-502 IN denotes if
T12962 503-510 VBN denotes started
T12963 511-516 RB denotes early
T12964 517-523 RB denotes enough
T12965 524-526 IN denotes in
T12966 527-530 DT denotes the
T12967 531-537 NN denotes course
T12968 538-540 IN denotes of
T12969 541-548 NN denotes disease
T12970 548-550 , denotes ,
T12971 550-559 NN denotes secretase
T12972 560-570 NNS denotes inhibitors
T12973 571-576 RB denotes alone
T12974 577-582 MD denotes could
T12959 583-590 VB denotes provide
T12975 591-602 JJ denotes substantial
T12976 603-610 NN denotes benefit
T12977 611-613 IN denotes in
T12978 614-621 VBG denotes slowing
T12979 622-632 JJ denotes pathogenic
T12980 633-642 NNS denotes processes
T12981 643-649 VBN denotes linked
T12982 650-652 IN denotes to
T12983 653-660 NN denotes amyloid
T12984 661-671 NN denotes deposition
T12985 671-672 . denotes .
T12986 672-907 sentence denotes Even at later stages in the disease, the presence of substantial microglial activation in human AD [40] suggests that simply slowing the formation of new amyloid deposits may allow ongoing phagocytosis to diminish preexisting lesions.
T12987 673-677 RB denotes Even
T12988 678-680 IN denotes at
T12990 681-686 JJR denotes later
T12991 687-693 NNS denotes stages
T12992 694-696 IN denotes in
T12993 697-700 DT denotes the
T12994 701-708 NN denotes disease
T12995 708-710 , denotes ,
T12996 710-713 DT denotes the
T12997 714-722 NN denotes presence
T12998 723-725 IN denotes of
T12999 726-737 JJ denotes substantial
T13001 738-748 JJ denotes microglial
T13000 749-759 NN denotes activation
T13002 760-762 IN denotes in
T13003 763-768 JJ denotes human
T13004 769-771 NN denotes AD
T13005 772-773 -LRB- denotes [
T13006 773-775 CD denotes 40
T13007 775-776 -RRB- denotes ]
T12989 777-785 VBZ denotes suggests
T13008 786-790 IN denotes that
T13010 791-797 RB denotes simply
T13011 798-805 VBG denotes slowing
T13012 806-809 DT denotes the
T13013 810-819 NN denotes formation
T13014 820-822 IN denotes of
T13015 823-826 JJ denotes new
T13017 827-834 NN denotes amyloid
T13016 835-843 NNS denotes deposits
T13018 844-847 MD denotes may
T13009 848-853 VB denotes allow
T13019 854-861 JJ denotes ongoing
T13020 862-874 NN denotes phagocytosis
T13022 875-877 TO denotes to
T13021 878-886 VB denotes diminish
T13023 887-898 JJ denotes preexisting
T13024 899-906 NNS denotes lesions
T13025 906-907 . denotes .
T13026 907-1146 sentence denotes However, the development of safe and effective secretase inhibitors will ultimately be required to determine whether the human brain has the capacity to repair amyloid-associated damage of AD once the progression of pathology is arrested.
T13027 908-915 RB denotes However
T13029 915-917 , denotes ,
T13030 917-920 DT denotes the
T13031 921-932 NN denotes development
T13032 933-935 IN denotes of
T13033 936-940 JJ denotes safe
T13035 941-944 CC denotes and
T13036 945-954 JJ denotes effective
T13037 955-964 NN denotes secretase
T13034 965-975 NNS denotes inhibitors
T13038 976-980 MD denotes will
T13039 981-991 RB denotes ultimately
T13040 992-994 VB denotes be
T13028 995-1003 VBN denotes required
T13041 1004-1006 TO denotes to
T13042 1007-1016 VB denotes determine
T13043 1017-1024 IN denotes whether
T13045 1025-1028 DT denotes the
T13047 1029-1034 JJ denotes human
T13046 1035-1040 NN denotes brain
T13044 1041-1044 VBZ denotes has
T13048 1045-1048 DT denotes the
T13049 1049-1057 NN denotes capacity
T13050 1058-1060 TO denotes to
T13051 1061-1067 VB denotes repair
T13052 1068-1075 NN denotes amyloid
T13054 1075-1076 HYPH denotes -
T13053 1076-1086 VBN denotes associated
T13055 1087-1093 NN denotes damage
T13056 1094-1096 IN denotes of
T13057 1097-1099 NN denotes AD
T13058 1100-1104 IN denotes once
T13060 1105-1108 DT denotes the
T13061 1109-1120 NN denotes progression
T13062 1121-1123 IN denotes of
T13063 1124-1133 NN denotes pathology
T13064 1134-1136 VBZ denotes is
T13059 1137-1145 VBN denotes arrested
T13065 1145-1146 . denotes .
R9171 T12874 T12875 prep In,demonstrate
R9173 T12876 T12874 pobj summary,In
R9175 T12877 T12875 punct ", ",demonstrate
R9176 T12878 T12875 nsubj we,demonstrate
R9178 T12879 T12880 mark that,halts
R9179 T12880 T12875 ccomp halts,demonstrate
R9181 T12881 T12880 csubj abrogating,halts
R9182 T12882 T12883 compound Aβ,production
R9183 T12883 T12881 dobj production,abrogating
R9184 T12934 T12932 advcl limit,therapies
R9185 T12884 T12885 det the,progression
R9186 T12885 T12880 dobj progression,halts
R9187 T12886 T12885 prep of,progression
R9188 T12887 T12888 amod pathologic,changes
R9189 T12935 T12936 compound Aβ,production
R9190 T12888 T12886 pobj changes,of
R9191 T12889 T12885 prep in,progression
R9192 T12890 T12891 det a,model
R9193 T12936 T12934 dobj production,limit
R9194 T12891 T12889 pobj model,in
R9195 T12892 T12891 amod transgenic,model
R9196 T12937 T12934 punct ", ",limit
R9197 T12893 T12891 compound mouse,model
R9198 T12894 T12891 prep of,model
R9199 T12895 T12896 compound Alzheimer,type
R9200 T12938 T12934 conj increase,limit
R9201 T12896 T12898 compound type,amyloidosis
R9202 T12897 T12896 punct -,type
R9203 T12898 T12894 pobj amyloidosis,of
R9204 T12939 T12940 compound Aβ,degradation
R9205 T12899 T12875 punct .,demonstrate
R9206 T12901 T12902 advmod However,are
R9207 T12940 T12938 dobj degradation,increase
R9208 T12903 T12902 punct ", ",are
R9209 T12941 T12938 punct ", ",increase
R9210 T12904 T12902 prep despite,are
R9211 T12905 T12906 amod dramatic,reductions
R9212 T12906 T12904 pobj reductions,despite
R9213 T12907 T12906 prep in,reductions
R9214 T12908 T12909 compound Aβ,synthesis
R9215 T12909 T12907 pobj synthesis,in
R9216 T12942 T12938 cc and,increase
R9217 T12910 T12902 punct ", ",are
R9218 T12911 T12912 amod neuritic,plaques
R9219 T12943 T12938 conj enhance,increase
R9220 T12912 T12902 nsubj plaques,are
R9221 T12913 T12914 amod stable,structures
R9222 T12914 T12902 attr structures,are
R9223 T12944 T12943 dobj phagocytosis,enhance
R9224 T12915 T12916 advmod in,vivo
R9225 T12916 T12914 advmod vivo,structures
R9226 T12945 T12944 prep of,phagocytosis
R9227 T12917 T12918 dep that,disaggregate
R9228 T12918 T12914 relcl disaggregate,structures
R9229 T12919 T12918 aux do,disaggregate
R9230 T12946 T12947 amod deposited,amyloid
R9231 T12920 T12918 neg not,disaggregate
R9232 T12921 T12918 advmod quickly,disaggregate
R9233 T12947 T12945 pobj amyloid,of
R9234 T12922 T12902 punct .,are
R9235 T12948 T12928 aux may,required
R9236 T12924 T12925 nsubj It,is
R9237 T12926 T12925 acomp possible,is
R9238 T12949 T12928 auxpass be,required
R9239 T12927 T12928 mark that,required
R9240 T12928 T12925 ccomp required,is
R9241 T12929 T12930 det a,combination
R9242 T12950 T12951 aux to,reverse
R9243 T12930 T12928 nsubjpass combination,required
R9244 T12931 T12930 prep of,combination
R9245 T12951 T12928 advcl reverse,required
R9246 T12932 T12931 pobj therapies,of
R9247 T12933 T12934 aux to,limit
R9248 T12952 T12951 dobj damage,reverse
R9249 T12953 T12952 acl associated,damage
R9250 T12954 T12953 prep with,associated
R9251 T13040 T13028 auxpass be,required
R9252 T12955 T12954 pobj AD,with
R9253 T12956 T12925 punct .,is
R9254 T13041 T13042 aux to,determine
R9255 T13042 T13028 advcl determine,required
R9256 T12958 T12959 advmod However,provide
R9257 T13043 T13044 mark whether,has
R9258 T13044 T13042 ccomp has,determine
R9259 T13045 T13046 det the,brain
R9260 T12960 T12959 punct ", ",provide
R9261 T13046 T13044 nsubj brain,has
R9262 T13047 T13046 amod human,brain
R9263 T13048 T13049 det the,capacity
R9264 T12961 T12962 mark if,started
R9265 T13049 T13044 dobj capacity,has
R9266 T12962 T12959 advcl started,provide
R9267 T13050 T13051 aux to,repair
R9268 T13051 T13049 acl repair,capacity
R9269 T12963 T12964 advmod early,enough
R9270 T13052 T13053 npadvmod amyloid,associated
R9271 T13053 T13055 amod associated,damage
R9272 T13054 T13053 punct -,associated
R9273 T12964 T12962 advmod enough,started
R9274 T13055 T13051 dobj damage,repair
R9275 T13056 T13055 prep of,damage
R9276 T13057 T13056 pobj AD,of
R9277 T12965 T12962 prep in,started
R9278 T13058 T13059 mark once,arrested
R9279 T13059 T13051 advcl arrested,repair
R9280 T12966 T12967 det the,course
R9281 T13060 T13061 det the,progression
R9282 T13061 T13059 nsubjpass progression,arrested
R9283 T13062 T13061 prep of,progression
R9284 T12967 T12965 pobj course,in
R9285 T13063 T13062 pobj pathology,of
R9286 T13064 T13059 auxpass is,arrested
R9287 T13065 T13028 punct .,required
R9288 T12968 T12967 prep of,course
R9289 T12969 T12968 pobj disease,of
R9290 T12970 T12959 punct ", ",provide
R9291 T12971 T12972 compound secretase,inhibitors
R9292 T12972 T12959 nsubj inhibitors,provide
R9293 T12973 T12972 advmod alone,inhibitors
R9294 T12974 T12959 aux could,provide
R9295 T12975 T12976 amod substantial,benefit
R9296 T12976 T12959 dobj benefit,provide
R9297 T12977 T12976 prep in,benefit
R9298 T12978 T12977 pcomp slowing,in
R9299 T12979 T12980 amod pathogenic,processes
R9300 T12980 T12978 dobj processes,slowing
R9301 T12981 T12980 acl linked,processes
R9302 T12982 T12981 prep to,linked
R9303 T12983 T12984 compound amyloid,deposition
R9304 T12984 T12982 pobj deposition,to
R9305 T12985 T12959 punct .,provide
R9306 T12987 T12988 advmod Even,at
R9307 T12988 T12989 prep at,suggests
R9308 T12990 T12991 amod later,stages
R9309 T12991 T12988 pobj stages,at
R9310 T12992 T12991 prep in,stages
R9311 T12993 T12994 det the,disease
R9312 T12994 T12992 pobj disease,in
R9313 T12995 T12989 punct ", ",suggests
R9314 T12996 T12997 det the,presence
R9315 T12997 T12989 nsubj presence,suggests
R9316 T12998 T12997 prep of,presence
R9317 T12999 T13000 amod substantial,activation
R9318 T13000 T12998 pobj activation,of
R9319 T13001 T13000 amod microglial,activation
R9320 T13002 T12997 prep in,presence
R9321 T13003 T13004 amod human,AD
R9322 T13004 T13002 pobj AD,in
R9323 T13005 T13006 punct [,40
R9324 T13006 T13004 parataxis 40,AD
R9325 T13007 T13006 punct ],40
R9326 T13008 T13009 mark that,allow
R9327 T13009 T12989 ccomp allow,suggests
R9328 T13010 T13011 advmod simply,slowing
R9329 T13011 T13009 csubj slowing,allow
R9330 T13012 T13013 det the,formation
R9331 T13013 T13011 dobj formation,slowing
R9332 T13014 T13013 prep of,formation
R9333 T13015 T13016 amod new,deposits
R9334 T13016 T13014 pobj deposits,of
R9335 T13017 T13016 compound amyloid,deposits
R9336 T13018 T13009 aux may,allow
R9337 T13019 T13020 amod ongoing,phagocytosis
R9338 T13020 T13021 nsubj phagocytosis,diminish
R9339 T13021 T13009 ccomp diminish,allow
R9340 T13022 T13021 aux to,diminish
R9341 T13023 T13024 amod preexisting,lesions
R9342 T13024 T13021 dobj lesions,diminish
R9343 T13025 T12989 punct .,suggests
R9344 T13027 T13028 advmod However,required
R9345 T13029 T13028 punct ", ",required
R9346 T13030 T13031 det the,development
R9347 T13031 T13028 nsubjpass development,required
R9348 T13032 T13031 prep of,development
R9349 T13033 T13034 amod safe,inhibitors
R9350 T13034 T13032 pobj inhibitors,of
R9351 T13035 T13033 cc and,safe
R9352 T13036 T13033 conj effective,safe
R9353 T13037 T13034 compound secretase,inhibitors
R9354 T13038 T13028 aux will,required
R9355 T13039 T13028 advmod ultimately,required